Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, and Viralgen, a leading contract development and manufacturing organization ...
Applied Biopharm Consulting Ltd has been awarded an Intellectual Property (IP) Start Grant from the Local Enterprise Office under Enterprise Ireland’s IP Strategy initiative. The grant will support ...
Altesa BioSciences will present novel data regarding the mechanisms of action and anti-viral coverage of vapendavir and its newly discovered active metabolites at the 39th International Conference on ...
A novel bioengineering strategy utilizing peptide display technology on the AAV1 capsid has successfully generated ...
The FDA granted priority review, with a decision expected by June 19, 2025. LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...
U.K. scientists have used mass spectrometry to look in detail at how adeno-associated viruses (AAVs) release their genetic cargo when infecting host cells. The team, from the University of Leeds, ...
From a virus's point of view, invading our cells is a matter of survival. The virus makes a living by highjacking cellular processes to produce more of the proteins that make it up. From our point of ...
A significant advancement in molecular engineering has produced a large, hollow spherical shell nanostructure through the self-assembly of peptides and metal ions, report researchers from Japan. This ...
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a groundbreaking twice-yearly injectable HIV-1 capsid inhibitor for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results